Release Date: November 25, 2025
Expiration Date: November 25, 2026
Time to Complete Activity: 1.0 hour

Faculty 

Leslie Citrome, MD, MPH
Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, NY

Christoph U. Correll, MD
Clinical Professor of Psychiatry and Molecular Medicine
The Donald and Barbar Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY
Professor and Chair, Department of Child and Adolescent Psychiatry
Charité Universitätsmedizin Berlin 
Berlin, Germany

 

Target Audience 

This activity has been designed to address the educational needs of psychiatry clinicians, including physicians, nurse practitioners, PAs, and nurses involved in the treatment of patients with schizophrenia.
 

Educational Provider 

This activity is provided by Paradigm Medical Communications, LLC.  
 

Supporter Acknowledgment 

This activity is supported by educational grants from Johnson & Johnson and Teva Pharmaceuticals, USA, Inc.
 

Program Overview 

This dynamic CME program blends interactive case consultations with a data-driven deep dive into long-acting injectables (LAIs) for schizophrenia. Through engaging real-world scenarios, learners will explore barriers and biases that influence LAI utilization and discover communication strategies that foster shared decision-making with patients and caregivers. A comprehensive evidence review highlights innovative LAIs, their attributes, and the latest clinical trial findings, offering practical insights for treatment planning. This unique format equips clinicians with both the knowledge and the skills to optimize adherence, improve outcomes, and confidently integrate LAIs into patient care.
 

Learning Objectives

Upon completion of this activity, participants should be able to:

• Identify the factors that contribute to suboptimal utilization of LAIs for the treatment of patients with schizophrenia 
• Employ impartial, person-centered communication strategies to LAI treatment discussions with patients with schizophrenia and their caregivers
• Describe the nuances of second-generation LAIs for the treatment of schizophrenia, including pharmacology, drug characteristics, and available clinical and real-world evidence

Physician Accreditation Statement

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

Physician Credit Designation Statement

Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

PA Continuing Education 

PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
 

Nurse Practitioner Continuing Education 

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
 

Hardware/Software Requirements

This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader

Technical Support: If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.
 

Instructions for Participation

To receive a certificate and claim credit, participants must:

• Follow instructions to register or log in with your professional information and complete the pretest
• View the online activity in its entirety
• Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.

There are no fees for participating in this activity.
 

Disclosure of Relevant Financial Relationships

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.

All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated.

Leslie Citrome, MD, MPH
Consultant: Acadia Pharmaceuticals Inc.; Adamas Pharmaceuticals, Inc; AdhereTech LLC; Allergan, Inc.; Alkermes; Alumis Inc.; Angelini Pharma S.p.A.; Astellas Pharma US, Inc; Autobahn Therapeutics; Axsome Therapeutics, Inc.; Biogen; BioXcel Therapeutics Inc.; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Cerevel Therapeutics; Clinilabs; Compass Therapeutics, Inc.; Delpor, Inc.; Draig Therapeutics; Eisai Inc.; Enteris BioPharma; HLS Therapeutics Inc.; Idorsia Pharmaceuticals Ltd; Impel Pharmaceuticals; INmuneBIO; Janssen Pharmaceuticals, Inc; Johnson & Johnson Services, Inc; Lundbeck; Luye Pharma Group; Lyndra Therapeutics; MapLight; Marvin Pharma Ltd; MedAvante-ProPhase; Merck & Co, Inc; Mitsubishi Tanabe Pharma; Neumora; Neurelis, Inc; Neurocrine Biosciences, Inc.; Noema Pharma; Novartis AG; Noven Pharmaceuticals, Inc.; Otsuka America Pharmaceuticals, Inc; Ovid Therapeutics; Praxis Precision Medicines, Inc.; Recordati; Relmada Therapeutics; Reviva Pharmaceuticals; Sage Therapeutics, Inc; Sumitomo Corporation; Supernus Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd; Vanda Pharmaceuticals
Speakers’ Bureau: Acadia Pharmaceuticals Inc.; Allergan, Inc; Alkermes; Angelini Pharma S.p.A.; Axsome Therapeutics, Inc.; BioXcel Therapeutics Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc; Johnson & Johnson Services, Inc; Lundbeck; Neurocrine Biosciences, Inc.; Neopharm Labs; Noven Pharmaceuticals, Inc.; Otsuka America Pharmaceuticals, Inc; Recordati; Sage Therapeutics, Inc; Sumitomo Corporation; Takeda Pharmaceutical Company Ltd; Teva Pharmaceutical Industries Ltd; Vanda Pharmaceuticals 
Stocks: Bristol-Myers Squibb Company; Eli Lilly and Company; Johnson & Johnson Services, Inc; Merck & Co, Inc; Pfizer Inc; Reviva Pharmaceuticals

Christoph U. Correll, MD
Advisor: AbbVie Inc.; Alkermes; Allergan, Inc.; Angelini Pharma; Boehringer Ingelheim International GmbH;  Bristol-Myers Squibb Company; Cerevel Therapeutics; Compass; CSL Seqirus; Gedeon Richter Plc; Janssen Pharmaceuticals, Inc; Johnson & Johnson; Karuna Therapeutics; LB Pharmaceuticals; Life Science Therapeutics; Lundbeck; Medincell; Merck & Co, Inc; Neuraxpharm; Neurelis; Neurocrine Biosciences; Newron Pharmaceuticals SpA; Novo Nordisk A/S; Otsuka America Pharmaceuticals, Inc; Recordati SpA; ROVI Pharma Industrial Services, S.A.; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd; Vertex Pharmaceuticals Incorporated; Viatris Inc.
Consultant: AbbVie Inc.; Alkermes; Angelini Pharma; Autobahn Therapeutics; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Cerevel Therapeutics; CNX Therapeutics; Compass; CSL Seqirus; Darnitsa Pharmaceuticals; Delpor, Inc.; Draig Therapeutics; Eli Lilly and Company; EuMentis Therapeutics; Gedeon Richter Plc; GH Research; Hikma Pharmaceuticals PLC; Holmusk; Intra-Cellular Therapies; Janssen Pharmaceuticals, Inc; Johnson & Johnson; LB Pharmaceuticals; Lundbeck; MapLight Therapeutics, Inc.; Medincell; MedLink Global; Merck & Co, Inc; Mindpax; Mylan N.V.; Neumora Therapeutics, Inc.; Neuraxpharm; Neurelis; Neurocrine Biosciences; Neurosterix; NeuShen Therapeutics, Inc.; Newron Pharmaceuticals SpA; Noven Pharmaceuticals, Inc.; Novo Nordisk A/S; Orion Corporation; Otsuka America Pharmaceuticals, Inc; PPD Biotech Solutions; Recognify Life Sciences, Inc; Recordati SpA; Relmada Therapeutics, Inc.; Response Pharmaceuticals Inc.; Reviva Pharmaceuticals Holdings, Inc; ROVI Pharma Industrial Services, S.A.; Saladax Biomedical, Inc.; Sanofi; Servier Pharmaceuticals LLC; Sunovion Pharmaceuticals Inc; Sun Pharmaceutical Industries Ltd; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Ltd; Teva Pharmaceutical Industries Ltd; Terran Biosciences; Tolmar, Inc.; Vertex Pharmaceuticals Incorporated; Viatris Inc.; Xenon Pharmaceuticals Inc.
Research Funding: Boehringer Ingelheim International GmbH; Janssen Pharmaceuticals, Inc; Takeda Pharmaceutical Company Ltd
Royalties: Wolters Kluwer
Stocks: Kuleon Bioscience; LB Pharmaceuticals; MedLink Global; Mindpax; Quantic
Other (Honoraria): AbbVie Inc.; Angelini Pharma; Aristo Pharma; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Cerevel Therapeutics; CSL Seqirus;  Gedeon Richter Plc; Hikma Pharmaceuticals PLC; Intra-Cellular Therapies; Janssen Pharmaceuticals, Inc; Johnson & Johnson; Karuna Therapeutics; Lundbeck; Mitsubishi Tanabe Pharma America; Mylan N.V.; Otsuka America Pharmaceuticals, Inc; Recordati SpA; Sanofi; Sunovion Pharmaceuticals Inc; Tabuk Pharmaceuticals; Takeda Pharmaceutical Company Ltd; Teva Pharmaceutical Industries Ltd; Viatris Inc.
Other (Expert Testimony): Janssen Pharmaceuticals, Inc; Lundbeck; Neurocrine Biosciences; Otsuka America Pharmaceuticals, Inc
Other (DSMB): Compass; Intra-Cellular Therapies; Relmada Therapeutics, Inc.; Reviva Pharmaceuticals Holdings, Inc; ROVI Pharma Industrial Services, S.A.

Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.

Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.
 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
 

Disclaimer

This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program and may be used to track registration and participation. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not otherwise transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
 

Contact Us

If you have any questions or comments, please email us at contactus@paradigmmc.com.

© 2025 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.